- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01026441
Clinical Study to Evaluate the Safety and Efficacy of the Vela100
May 4, 2011 updated by: Syneron Medical
Clinical Study to Evaluate the Safety and Efficacy of the Vela100/eShape Uno Device for Cellulite and Circumference Reduction
This study is intended to test the safety of the Vela100 device when used for treatment for cellulite and circumference temporary reduction.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
60
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Laguna Hills, California, United States, 92653
- Orange Coast Women's Medical Group
-
-
Georgia
-
Atlanta, Georgia, United States, 30342
- Kavali Plastic Surgery and Skin Renewal Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
21 years to 60 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Informed consent agreement signed by the subject.
- Healthy males or females older than 21 years of age but not older than 60 years of age.
- Fitzpatrick Skin Type I to VI
- Having at least two areas (abdomen, buttocks and thighs) suitable for treatment.
- BMI score is greater than 18.5 and less than 29.9 - normal to overweight, but not obese.
- Willingness to follow the treatment and follow-up schedule and the post-treatment care.
- Willingness to refrain from a change in diet/drinking/exercise/medication regimen for the entire course of the study.
- For female of child bearing potential - using a medically acceptable form of birth control at least 3 months prior to enrollment and during the entire course of the study (i.e., oral contraceptives, IUD, contraceptive implant, barrier methods with spermicide, or abstinence).
Exclusion Criteria:
- Pregnant or planning to become pregnant, having given birth (vaginal birth or Caesarean surgery) less than 9 months ago, and/or breastfeeding.
- Having any active electrical implant anywhere in the body, such as a pacemaker or an internal defibrillator.
- Having a permanent implant in the treated areas, such as metal plates and screws or an injected chemical substance.
- Having received treatment with laser, RF or other devices in the treated areas within 6 months of treatment or during the study.
- Having undergone a liposuction surgery or any contouring treatment in the areas intended for treatment within 9 months of treatment or during the study.
- For post-liposuction areas, the procedure should also not have been performed more than 2 years prior to this study.
- Having undergone any other surgery in the treated areas within 9 months of treatment or during the study.
- Having or undergoing any form of treatment for active cancer, or having a history of skin cancer or any other cancer in the areas to be treated, including presence of malignant or pre-malignant pigmented lesions.
- Suffering from significant concurrent illness, such as cardiac disorders, diabetes (type I or II), lupus, porphyria, or pertinent neurological disorders.
- Having a known anticoagulative or thromboembolic condition or taking anticoagulation medications one week prior to and during the treatment course (to allow inclusion, temporary cessation of use as per the subject's physician discretion).
- History of immunosuppression/immune deficiency disorders (including HIV infection or AIDS) or currently using immunosuppressive medications.
- Suffering from hormonal imbalance which may affect weight or cellulite, as per the Investigator's discretion.
- History of significant lymphatic drainage problems. Suffering from significant skin conditions in the treated areas or inflammatory skin conditions, including, but not limited to, open lacerations or abrasions and active cold sores or herpes sores prior to treatment (duration of resolution as per the Investigator's discretion) or during the treatment course.
- History of keloid scarring or of abnormal wound healing.
- History of being especially prone to bruising.
- History of epidermal or dermal disorders (particularly if involving collagen or microvascularity).
- Use of isotretinoin (Accutane®) within 6 months of treatment or during the study.
- Use of non-steroidal anti-inflammatory drugs (NSAIDS, e.g., ibuprofen-containing agents) during, as well as two weeks before and after, the treatment course.
- Use of anti-cellulite creams within a month of treatment or during the course of the study.
- If any allergy that is related to the lotion used in this study appears, subjects may be excluded from the study.
- Recently tanned in areas to be treated and/or unable or unlikely to refrain from tanning during the study.
- Significant change in diet or exercise regimen within a month of enrollment or during this study and/or weight loss or gain of 10 lbs (4.5 kgs) within 2 months of enrollment or during this study.
- Participation in a study of another device or drug within 1 month prior to enrollment or during this study.
- As per the Investigator's discretion, any physical or mental condition which might make it unsafe for the subject to participate in this study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Treatment for cellulite and circumference reduction
All subjects will be treated with the device
|
6 treatments once a week
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Adverse Events
Time Frame: End of treatment, at 1 month FU
|
End of treatment, at 1 month FU
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2008
Primary Completion (Actual)
October 1, 2008
Study Completion (Actual)
October 1, 2008
Study Registration Dates
First Submitted
December 3, 2009
First Submitted That Met QC Criteria
December 3, 2009
First Posted (Estimate)
December 4, 2009
Study Record Updates
Last Update Posted (Estimate)
May 5, 2011
Last Update Submitted That Met QC Criteria
May 4, 2011
Last Verified
May 1, 2011
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Vela100
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Circumference Reduction
-
Erchonia CorporationCompletedCircumference ReductionUnited States
-
Syneron MedicalCompletedCircumference ReductionUnited States
-
Syneron CandelaUnknown
-
Erchonia CorporationCompletedCircumference ReductionUnited States
-
Erchonia CorporationTerminatedCircumference ReductionUnited States
-
Erchonia CorporationCompletedCircumference ReductionUnited States
-
UltraShapeUnknownReduction in Abdominal CircumferenceIsrael
-
InMode MD Ltd.Active, not recruitingCircumference Reduction of AbdomenUnited States
-
InMode MD Ltd.CompletedNon-invasive Circumference ReductionUnited States
-
Alma Lasers Inc.Unknown
Clinical Trials on Vela100 (Aesthetic)
-
Goldman, Butterwick, Fitzpatrick and GroffGalderma R&DRecruiting
-
Institut BergoniéCompleted
-
Centro de Atenção ao Assoalho PélvicoRecruitingLaxity; Skin | Skin Hyperpigmentation | Needlestick PunctureBrazil
-
University of SienaCompletedAesthetic Evaluation | Implant Survival RateItaly
-
Universidade Federal de AlfenasCompletedTooth Eruption DisorderBrazil
-
University Hospital, LilleRecruitingAcute Leukemia | Aplasia | Hematopoietic Stem Cell Transplantation (SCT)France
-
Tokat Gaziosmanpasa UniversityCompletedGingival Recession | Gingival EnlargementTurkey
-
Bellus Medical, LLCCompleted
-
University Hospital, AngersCompleted